Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Maze Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Maze Therapeutics, Inc.

MAZE

Maze Therapeutics, Inc.

About Maze Therapeutics, Inc.

Maze Therapeutics is a biopharmaceutical company focused on developing precision medicines for renal, cardiovascular, and metabolic diseases. Using its proprietary Compass platform, it identifies genetic variants linked to disease and creates targeted small molecule therapies. Its pipeline includes treatments for chronic kidney disease, especially APOL1-related kidney disorders, aiming to address underlying genetic drivers and improve patient outcomes through innovative, genetically informed drug development.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Maze Therapeutics, Inc.

1
1
Maze Therapeutics, Inc. Maze Therapeutics Reports $20 Million License Revenue and $24.2 Million Net Loss in Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Maze Therapeutics, Inc. Maze Therapeutics Reports $131.1 Million Net Loss for 2025, Advances Clinical Pipeline

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Maze Therapeutics, Inc. Maze Therapeutics Reports No License Revenue and $30.1 Million Net Loss for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Maze Therapeutics, Inc. Maze Therapeutics Reports No Revenue and $33.7 Million Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Maze Therapeutics, Inc. Maze Therapeutics Reports Q1 2025 Financial Results with $32.8M Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments